Navigation Links
FDA Grants Fast Track Designation to CTI BioPharma's Pacritinib, a Novel JAK2 Inhibitor for the Treatment of Myelofibrosis
Date:8/6/2014

re application can be reviewed. NDA review usually does not begin until the company has submitted the entire application to the FDA. A drug program with Fast Track designation enables the company to have early and frequent communication with the FDA in the development and review of the product candidate, often leading to faster drug approval and access by patients.

About the PERSIST Phase 3 Development Program of Pacritinib

Based on pacritinib's efficacy and tolerability profile demonstrated to date, CTI is pursuing a broad approach to advancing this therapy for patients with myelofibrosis by conducting two Phase 3 clinical trials: one in a broad set of patients without limitations on blood platelet counts, the PERSIST-1 trial, and the other in patients with low platelet counts, the PERSIST-2 trial.

PERSIST-1:
In July 2014, CTI completed enrollment in the PERSIST-1 trial that was designed to enroll approximately 320 patients and is a randomized, open-label, multicenter trial comparing the efficacy and safety of pacritinib with that of best available therapy, other than JAK inhibitors, in patients with primary myelofibrosis, post-polycythemia vera myelofibrosis or post-essential thrombocythemia myelofibrosis, without exclusion for low platelet counts. The primary endpoint is the percentage of patients achieving a greater than or equal to 35 percent reduction in spleen volume measured by MRI or CT from baseline to 24 weeks of treatment.

PERSIST-2:
In March 2014, CTI announced the initiation of the PERSIST-2 trial, which will evaluate pacritinib compared to best available therapy, including approved JAK2 inhibitors that are dosed according to product label, in patients with myelofibrosis whose platelet counts are less than or equal to 100,000/uL. The trial is designed to enroll up to 300 patients in North America, Europe, Australia and New Zealand. In October 2013, CTI reac
'/>"/>

SOURCE CTI BioPharma
Copyright©2014 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. PTC Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
2. US Patent Office Grants McCord Research Endothelial Cell Treatment Patent
3. FDA Grants Astellas Qualified Infectious Disease Product Designation for Isavuconazole for the Treatment of Invasive Candidiasis
4. FDA Grants Orphan Drug Designation to Omeros OMS721 for Complement-Mediated Thrombotic Microangiopathies
5. FDA Grants Approval of IND to Commence a Phase 3 Pivotal Study for ST10 for the Treatment of Iron Deficiency Anaemia in Chronic Kidney Disease
6. Auxilium Pharmaceuticals, Inc. Announces Court Grants Upsher-Smith Laboratories Motion For Summary Judgment
7. FDA Grants Astellas Qualified Infectious Disease Product Designation for Isavuconazole for the Treatment of Invasive Aspergillosis
8. RadSite Grants Accreditation to First Wave of MIPPA Program Applicants
9. NASDAQ Grants China Jo-Jo Drugstores 180-Day Extension to Regain Compliance with Bid Price Requirement
10. U.S. FDA Grants Orphan Drug Designation for KaloBios KB001-A in Treatment of Cystic Fibrosis Patients
11. FDA Grants 510(k) Clearance for Innovative Fuse Gastroscope from EndoChoice
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2015)... July 31, 2015 Today, the National ... ® ) issued a report urging greater accountability ... is taken against websites illegally selling medications online. ... Outlet Identification Program Progress Report for State and ... thousands of websites illegally distribute medications and avoid ...
(Date:7/31/2015)...  Boston Children,s Hospital physicians report the first ... their anatomy before undergoing high-risk brain procedures. The ... the brain,s blood vessels) that posed special treatment ... Journal of Neurosurgery: Pediatrics , the physicians ... resins to create custom, high-fidelity models of the ...
(Date:7/31/2015)... Quietly, sedately, Morocco,s pharmaceutical sector is shining. ... is strong, with a well-developed base of local producers ... One place where the quality of Moroccan pharma ... quietly become the second largest African exporter of drugs ... Moroccan pharma companies have been making inroads as exporters ...
Breaking Medicine Technology:NABP Stresses Need for Accountability in Enforcing Internet Policies to Protect the Public From Illegal Online Drug Sellers 2NABP Stresses Need for Accountability in Enforcing Internet Policies to Protect the Public From Illegal Online Drug Sellers 33D Printing Helps Doctors Rehearse Complex Brain Procedures 23D Printing Helps Doctors Rehearse Complex Brain Procedures 33D Printing Helps Doctors Rehearse Complex Brain Procedures 4PharmaBoardroom Releases New Morocco Pharmaceuticals Report 2PharmaBoardroom Releases New Morocco Pharmaceuticals Report 3
... KENILWORTH, N.J., Oct. 12 Schering-Plough Corporation (NYSE: SGP ... for the 2009 third quarter on Thursday, Oct. 22, 2009. ... day, Schering-Plough will conduct a conference call to review results ... and CEO, and other members of management will host the ...
... today announced that the InterPlate® C-Ti has been cleared for ... in 2007, the C-Ti was the first system cleared by ... recent announcement, the C-Ti has now become the first interbody ... as well. , RSB Spine Chief Executive Officer John A. ...
Cached Medicine Technology:Schering-Plough Schedules Conference Call Webcast For 2009 Third Quarter Earnings 2
(Date:8/1/2015)... ... , ... Have you ever wondered what “Karma” really means? Does it even exist? Can I ... Vedic tradition, which gave birth to Hinduism, is one of the most ancient spiritual and ... tradition. According to the wisdom of this heritage, Karma is a very real and powerful ...
(Date:8/1/2015)... ... August 01, 2015 , ... ... L.P. (“GPP”) portfolio company has acquired Premier Physical Therapy & Wellness (“Premier”) — ... portfolio of state-of-the-art clinics. , “Our acquisition of Premier Physical Therapy & Wellness ...
(Date:8/1/2015)... ... 01, 2015 , ... On March 19, 2015 Phil Valentine – the Executive Director of Connecticut ... Trail by stepping off Springer Mountain and heading north. Since that day, Phil has ... Connecticut and was greeted by friends and family. He visited CCAR and left an ...
(Date:7/31/2015)... Santa Clara, CA (PRWEB) , ... August 01, 2015 , ... Super Bowl 50 ... The National Football League’s biggest day each year is the Super Bowl. In the ... buildup that takes place from the host venue. The 2016 Super Bowl game will mark ...
(Date:7/31/2015)... ... 31, 2015 , ... The 2nd annual Ride to Fight On will start ... 3, 2015. The Ride to Fight On is a cycling fundraiser that benefits the ... West Clinic and The University of Tennessee Health Science Center. A health and wellness ...
Breaking Medicine News(10 mins):Health News:Nithyananda Yoga Foundation to Conduct Global Webinar on Karma at No Charge on August 1st 2Health News:Professional Physical Therapy Now Largest Outpatient Physical Therapy Provider in Northeast With Acquisition of Premier Physical Therapy & Wellness 2Health News:Connecticut Executive Hikes Appalachian Trail to Raise Awareness About Recovery. 2Health News:Cheap 2016 Super Bowl Tickets at Levi's Stadium: Ticket Down Slashes Ticket Prices on Super Bowl 50 Tickets in Santa Clara, CA at Levi's Stadium 2Health News:West Cancer Center Announces 2nd Annual Ride to Fight On 2Health News:West Cancer Center Announces 2nd Annual Ride to Fight On 3
... technology delivers new levels of analysis of heart,s ... NewCardio, Inc., (OTC Bulletin Board: NWCI) a ... members of the Company,s medical and technology teams ... from analytical and clinical applications of its proprietary ...
... of Upcoming ASCO PresentationBELLEVUE, Wash., May 18 Light ... preclinical study has yielded evidence that the company,s novel ... and prevent metastases. Results of the study will be ... Society of Clinical Oncology (ASCO) meeting in Orlando, Florida, ...
... First and Only Long-Acting Antipsychotic Therapy Available for ... Division of Ortho-McNeil-Janssen Pharmaceuticals, Inc. today announced the ... the Supplemental New Drug Applications (sNDAs) for the ... as both monotherapy and adjunctive therapy to lithium ...
... information technology and innovative partnerships help promote prevention ... 18 Target Corporation (NYSE: TGT ... wellness resources designed to support the company,s increased ... part of the company,s commitment to employees (called ...
... May 18 WaferGen Biosystems, Inc. (OTC Bulletin ... analysis systems, today announced two key appointments, naming ... of directors and Lincoln J. McBride, Ph.D., as ... scientific advisory board. With extensive life science ...
... Payments from New Galderma Collaboration Resulted in Positive ... NovaBay Pharmaceuticals, Inc. (NYSE Amex: NBY ... products for the treatment and prevention of a ... today its financial results and operational highlights for ...
Cached Medicine News:Health News:NewCardio Medical and Technology Team Presents Two Abstracts at Heart Rhythm Society Conference 2Health News:NewCardio Medical and Technology Team Presents Two Abstracts at Heart Rhythm Society Conference 3Health News:NewCardio Medical and Technology Team Presents Two Abstracts at Heart Rhythm Society Conference 4Health News:NewCardio Medical and Technology Team Presents Two Abstracts at Heart Rhythm Society Conference 5Health News:Light Sciences Oncology Announces Results of Study on Immunotherapeutic Mechanism of Aptocine(TM), a Novel Light-Activated Drug Therapy for Cancer 2Health News:Light Sciences Oncology Announces Results of Study on Immunotherapeutic Mechanism of Aptocine(TM), a Novel Light-Activated Drug Therapy for Cancer 3Health News:Light Sciences Oncology Announces Results of Study on Immunotherapeutic Mechanism of Aptocine(TM), a Novel Light-Activated Drug Therapy for Cancer 4Health News:FDA Grants Approval for Use of RISPERDAL(R) CONSTA(R) as Both a Monotherapy and Adjunctive Therapy in the Maintenance Treatment of Bipolar I Disorder 2Health News:FDA Grants Approval for Use of RISPERDAL(R) CONSTA(R) as Both a Monotherapy and Adjunctive Therapy in the Maintenance Treatment of Bipolar I Disorder 3Health News:FDA Grants Approval for Use of RISPERDAL(R) CONSTA(R) as Both a Monotherapy and Adjunctive Therapy in the Maintenance Treatment of Bipolar I Disorder 4Health News:FDA Grants Approval for Use of RISPERDAL(R) CONSTA(R) as Both a Monotherapy and Adjunctive Therapy in the Maintenance Treatment of Bipolar I Disorder 5Health News:FDA Grants Approval for Use of RISPERDAL(R) CONSTA(R) as Both a Monotherapy and Adjunctive Therapy in the Maintenance Treatment of Bipolar I Disorder 6Health News:FDA Grants Approval for Use of RISPERDAL(R) CONSTA(R) as Both a Monotherapy and Adjunctive Therapy in the Maintenance Treatment of Bipolar I Disorder 7Health News:FDA Grants Approval for Use of RISPERDAL(R) CONSTA(R) as Both a Monotherapy and Adjunctive Therapy in the Maintenance Treatment of Bipolar I Disorder 8Health News:FDA Grants Approval for Use of RISPERDAL(R) CONSTA(R) as Both a Monotherapy and Adjunctive Therapy in the Maintenance Treatment of Bipolar I Disorder 9Health News:FDA Grants Approval for Use of RISPERDAL(R) CONSTA(R) as Both a Monotherapy and Adjunctive Therapy in the Maintenance Treatment of Bipolar I Disorder 10Health News:Target Corporation Makes Getting and Staying Healthy Easier 2Health News:Target Corporation Makes Getting and Staying Healthy Easier 3Health News:Target Corporation Makes Getting and Staying Healthy Easier 4Health News:Target Corporation Makes Getting and Staying Healthy Easier 5Health News:Target Corporation Makes Getting and Staying Healthy Easier 6Health News:WaferGen Appoints Seasoned Industry Executives to Board of Directors and Scientific Advisory Board 2Health News:WaferGen Appoints Seasoned Industry Executives to Board of Directors and Scientific Advisory Board 3Health News:WaferGen Appoints Seasoned Industry Executives to Board of Directors and Scientific Advisory Board 4Health News:WaferGen Appoints Seasoned Industry Executives to Board of Directors and Scientific Advisory Board 5Health News:NovaBay Pharmaceuticals, Inc. Reports First Quarter 2009 Financial Results 2Health News:NovaBay Pharmaceuticals, Inc. Reports First Quarter 2009 Financial Results 3Health News:NovaBay Pharmaceuticals, Inc. Reports First Quarter 2009 Financial Results 4Health News:NovaBay Pharmaceuticals, Inc. Reports First Quarter 2009 Financial Results 5Health News:NovaBay Pharmaceuticals, Inc. Reports First Quarter 2009 Financial Results 6Health News:NovaBay Pharmaceuticals, Inc. Reports First Quarter 2009 Financial Results 7Health News:NovaBay Pharmaceuticals, Inc. Reports First Quarter 2009 Financial Results 8Health News:NovaBay Pharmaceuticals, Inc. Reports First Quarter 2009 Financial Results 9
For the qualitative detection of human Chorionic Gonadotrophin (hCG) in urine specimens...
For the qualitative detection of human Chorionic Gonadotrophin (hCG) in urine specimens...
For the qualitative detection of human Chorionic Gonadotrophin (HCG) in urine or urine and serum specimens...
For the qualitative detection of single and multiple drugs and drug metabolites in human urine...
Medicine Products: